Company press releases
Tid | Selskap | Tittel | Sektor | Kategori |
---|---|---|---|---|
20 Nov 2024 12:01 CET |
NAVAMEDIC | Major shareholder disclosure in Navamedic ASA | 20103015 Pharmaceuticals | Major shareholding notifications |
19 Nov 2024 10:43 CET |
NAVAMEDIC | Flaggemelding Navamedic (NAVA) | 20103015 Pharmaceuticals | Flagging |
15 Nov 2024 13:00 CET |
NAVAMEDIC | Navamedic ASA: Amendments to loan agreements with Observe Medical ASA | 20103015 Pharmaceuticals | Inside information |
06 Nov 2024 13:52 CET |
NAVAMEDIC | Navamedic ASA: Mandatory notice of trade | 20103015 Pharmaceuticals | Mandatory notification of trade primary insiders |
06 Nov 2024 09:10 CET |
NAVAMEDIC | Navamedic launches Eroxon[®] in Finland | 20103015 Pharmaceuticals | Non-regulatory press releases |
31 Oct 2024 07:00 CET |
NAVAMEDIC | Navamedic Q3 2024: Business remains strong in quarter impacted by cyclical nature of the business | 20103015 Pharmaceuticals | Half yearly financial reports and audit reports/limited reviews |
31 Oct 2024 07:00 CET |
NAVAMEDIC | Navamedic 3. kvartal 2024: Fortsatt solide resultater i et kvartal som er preget av at markedet er syklisk av natur | 20103015 Pharmaceuticals | Halvårsrapporter og revisjonsberetninger / uttalelser om forenklet revisorkontroll |
28 Oct 2024 09:09 CET |
NAVAMEDIC | Navamedic ASA: Invitation to 2024 3rd quarter presentation | 20103015 Pharmaceuticals | Additional regulated information required to be disclosed under the laws of a Member State |
07 Oct 2024 13:57 CEST |
NAVAMEDIC | Navamedic wins joint Nordic antibiotics tender | 20103015 Pharmaceuticals | Non-regulatory press releases |
19 Sep 2024 08:24 CEST |
NAVAMEDIC | Navamedic ASA - Registration of share capital increase | 20103015 Pharmaceuticals | Total number of voting rights and capital |
12 Sep 2024 12:00 CEST |
NAVAMEDIC | Navamedic announces an exclusive agreement with Alex Therapeutics for the development of a Companion App to aid in the treatment of Parkinson's Disease | 20103015 Pharmaceuticals | Ikke-informasjonspliktige pressemeldinger |
09 Sep 2024 16:47 CEST |
NAVAMEDIC | Navamedic ASA - Mandatory notification of trade by primary insider | 20103015 Pharmaceuticals | Mandatory notification of trade primary insiders |
09 Sep 2024 16:03 CEST |
NAVAMEDIC | NAVAMEDIC ASA: RESOLUTION TO INCREASE THE SHARE CAPITAL IN CONNECTION WITH EXERCISE OF EMPLOYEE OPTIONS | 20103015 Pharmaceuticals | Additional regulated information required to be disclosed under the laws of a Member State |
21 Aug 2024 17:20 CEST |
NAVAMEDIC | Navamedic ASA - Mandatory notice of trade | 20103015 Pharmaceuticals | Mandatory notification of trade primary insiders |
20 Aug 2024 17:31 CEST |
NAVAMEDIC | Navamedic ASA - Mandatory notice of trade | 20103015 Pharmaceuticals | Meldepliktig handel for primærinnsidere |
16 Aug 2024 07:00 CEST |
NAVAMEDIC | Navamedic 2. kvartal og H1 2024: Den stabile veksten fortsetter, understøttet av ny lisensavtale | 20103015 Pharmaceuticals | Halvårsrapporter og revisjonsberetninger / uttalelser om forenklet revisorkontroll |
16 Aug 2024 07:00 CEST |
NAVAMEDIC | Navamedic Q2 and H1 2024: Stable growth continues and is supported by a new licensing and supply agreement | 20103015 Pharmaceuticals | Half yearly financial reports and audit reports/limited reviews |
14 Aug 2024 12:22 CEST |
NAVAMEDIC | Major shareholder disclosure in Navamedic ASA | 20103015 Pharmaceuticals | Major shareholding notifications |
13 Aug 2024 15:36 CEST |
NAVAMEDIC | Major shareholder disclosure in Navamedic ASA | 20103015 Pharmaceuticals | Major shareholding notifications |
12 Aug 2024 10:00 CEST |
NAVAMEDIC | Navamedic ASA: Invitation to 2024 2nd quarter presentation | 20103015 Pharmaceuticals | Additional regulated information required to be disclosed under the laws of a Member State |
12 Jul 2024 20:59 CEST |
NAVAMEDIC | Navamedic ASA - Mandatory notification of trade | 20103015 Pharmaceuticals | Mandatory notification of trade primary insiders |
24 Jun 2024 16:19 CEST |
NAVAMEDIC | Navamedic and Orion Corporation sign License & Supply Agreement for Flexilev® in Europe | 20103015 Pharmaceuticals | Inside information |
04 Jun 2024 10:18 CEST |
NAVAMEDIC | Navamedic ASA: Minutes of Annual General Meeting | 20103015 Pharmaceuticals | Additional regulated information required to be disclosed under the laws of a Member State |
16 May 2024 09:00 CEST |
NAVAMEDIC | Navamedic ASA: Renewed contract for delivering antibiotics to Norwegian hospitals | 20103015 Pharmaceuticals | Non-regulatory press releases |
14 May 2024 14:10 CEST |
NAVAMEDIC | Navamedic ASA: Notice of Annual General Meeting | 20103015 Pharmaceuticals | Additional regulated information required to be disclosed under the laws of a Member State |
06 May 2024 11:00 CEST |
NAVAMEDIC | Navamedic ASA: Broad launch for Eroxon® in Sweden today | 20103015 Pharmaceuticals | Non-regulatory press releases |
06 May 2024 11:00 CEST |
NAVAMEDIC | Första behandlingen mot erektionsproblem utan recept lanseras på svenska apotek | 20103015 Pharmaceuticals | Ikke-informasjonspliktige pressemeldinger |
30 Apr 2024 17:45 CEST |
NAVAMEDIC | Navamedic ASA: Annual Report 2023 | 20103015 Pharmaceuticals | Annual financial and audit Reports |
30 Apr 2024 07:00 CEST |
NAVAMEDIC | Navamedic 1. kvartal 2024: Vellykket produktlansering og jevn fremgang i driften | 20103015 Pharmaceuticals | Halvårsrapporter og revisjonsberetninger / uttalelser om forenklet revisorkontroll |
30 Apr 2024 07:00 CEST |
NAVAMEDIC | Navamedic Q1 2024: Successful product launch and steady operational progress | 20103015 Pharmaceuticals | Half yearly financial reports and audit reports/limited reviews |
23 Apr 2024 14:30 CEST |
NAVAMEDIC | Navamedic ASA: Invitation to 2024 1st quarter presentation | 20103015 Pharmaceuticals | Additional regulated information required to be disclosed under the laws of a Member State |
05 Apr 2024 13:11 CEST |
NAVAMEDIC | NOTIFICATION OF MAJOR HOLDINGS | 20103015 Pharmaceuticals | Major shareholding notifications |
02 Apr 2024 14:38 CEST |
NAVAMEDIC | Navamedic ASA - Registration of share capital increase | 20103015 Pharmaceuticals | Kapital- og stemmerettsendringer |
21 Mar 2024 13:20 CET |
NAVAMEDIC | Disclosure in NAVAMEDIC ASA | 20103015 Pharmaceuticals | Major shareholding notifications |
18 Mar 2024 13:38 CET |
NAVAMEDIC | Major shareholder disclosure in Navamedic ASA | 20103015 Pharmaceuticals | Major shareholding notifications |
15 Mar 2024 13:30 CET |
NAVAMEDIC | Navamedic ASA - Mandatory notification of trade by primary insider | 20103015 Pharmaceuticals | Mandatory notification of trade primary insiders |
15 Mar 2024 11:52 CET |
NAVAMEDIC | Navamedic ASA: Resolution to increase the share capital in connection with exercise of employee options | 20103015 Pharmaceuticals | Additional regulated information required to be disclosed under the laws of a Member State |
13 Mar 2024 10:43 CET |
NAVAMEDIC | Navamedic welcomes new shareholders | 20103015 Pharmaceuticals | Non-regulatory press releases |
13 Mar 2024 09:04 CET |
NAVAMEDIC | Navamedic ASA – Notification of Major Holdings | 20103015 Pharmaceuticals | Major shareholding notifications |
12 Mar 2024 22:10 CET |
NAVAMEDIC | Navamedic ASA: Notification of major shareholding and mandatory notification of trade | 20103015 Pharmaceuticals | Major shareholding notifications |
12 Mar 2024 16:36 CET |
NAVAMEDIC | Contemplated block sale of existing shares in Navamedic ASA | 20103015 Pharmaceuticals | Announcement from other participants |
22 Feb 2024 19:31 CET |
NAVAMEDIC | Navamedic ASA: Mandatory notification of trade | 20103015 Pharmaceuticals | Mandatory notification of trade primary insiders |
20 Feb 2024 16:14 CET |
NAVAMEDIC | Navamedic ASA: Notification of major shareholding and mandatory notification of trade | 20103015 Pharmaceuticals | Flagging |
15 Feb 2024 08:00 CET |
NAVAMEDIC | Navamedic Q4 and full year 2023: A year marked by new records and transformative growth initiatives | 20103015 Pharmaceuticals | Half yearly financial reports and audit reports/limited reviews |
15 Feb 2024 08:00 CET |
NAVAMEDIC | Navamedic i Q4 og 2023: Et år preget av nye rekorder, oppkjøp og avtaler som vil gi videre vekst | 20103015 Pharmaceuticals | Halvårsrapporter og revisjonsberetninger / uttalelser om forenklet revisorkontroll |
13 Feb 2024 08:00 CET |
NAVAMEDIC | Navamedic ASA: Invitation to 2023 4th quarter presentation | 20103015 Pharmaceuticals | Additional regulated information required to be disclosed under the laws of a Member State |
12 Feb 2024 09:00 CET |
NAVAMEDIC | Navamedic ASA launches Eroxon® | 20103015 Pharmaceuticals | Non-regulatory press releases |
21 Dec 2023 17:20 CET |
NAVAMEDIC | Navamedic ASA: Renewed contract signed with Vitaflo International Limited | 20103015 Pharmaceuticals | Non-regulatory press releases |
15 Dec 2023 15:37 CET |
NAVAMEDIC | Financial calendar | 20103015 Pharmaceuticals | Additional regulated information required to be disclosed under the laws of a Member State |
15 Dec 2023 07:00 CET |
NAVAMEDIC | Navamedic ASA: Mandatory notification of trade | 20103015 Pharmaceuticals | Meldepliktig handel for primærinnsidere |